A prospective preconception cohort study of the association between Mycoplasma genitalium and fecundability in Kenyan women trying to conceive.
Mycoplasma genitalium
bacterial vaginosis
conception
fecundability
infertility
time-to-pregnancy
vaginal microbiota
Journal
Human reproduction (Oxford, England)
ISSN: 1460-2350
Titre abrégé: Hum Reprod
Pays: England
ID NLM: 8701199
Informations de publication
Date de publication:
03 10 2023
03 10 2023
Historique:
received:
06
12
2022
revised:
04
08
2023
pmc-release:
26
08
2024
medline:
4
10
2023
pubmed:
27
8
2023
entrez:
27
8
2023
Statut:
ppublish
Résumé
Is Mycoplasma genitalium-infection associated with reduced fecundability? Preconception M. genitalium-infection was associated with 27% lower fecundability though confidence intervals were wide, and the association between M. genitalium and fecundability may be dependent on concurrent bacterial vaginosis (BV). M. genitalium has been associated with cervicitis, pelvic inflammatory disease, infertility, and preterm birth, but the extent to which M. genitalium is causally related to adverse reproductive sequelae in women is debated. Kenyan women enrolled in a prospective preconception cohort provided vaginal fluid specimens and underwent monthly pregnancy testing. Stored samples from 407 women who had been trying to conceive for ≤6 months were tested for M. genitalium using a nucleic acid amplification test. Data on first day of last menstrual period, sexual behavior, pregnancy status, and vaginal specimens were collected at monthly preconception visits. The association between M. genitalium detected at the visit prior to each pregnancy test and fecundability was estimated using discrete time proportional probabilities models. Secondary analyses explored the influence of concurrent BV on the association between M. genitalium and fecundability. The 407 participants experienced 1220 menstrual cycles and 213 pregnancies. The prevalence of M. genitalium at enrollment was 7.7%. After adjustment for age, frequency of condomless sex in the last 4 weeks, and study site, M. genitalium was associated with a 27% lower fecundability, but confidence intervals were wide (adjusted fecundability ratio (aFR) 0.73, 95% CI 0.44, 1.23). In secondary analyses, when compared to cycles without M. genitalium or BV at the visit prior, women with both M. genitalium and BV at the visit prior had a 51% lower fecundability (aFR = 0.49, 95% CI 0.22, 1.09) whereas there was no association of M. genitalium alone (aFR = 0.98 (95% CI 0.54, 1.76)), and a smaller reduction in fecundability for women with BV only (aFR = 0.80 (95% CI 0.60, 1.07)). Results should be interpreted cautiously given the relatively low prevalence of M. genitalium and wide confidence intervals. In this cohort of Kenyan women trying to conceive, the association between M. genitalium and fecundability was influenced by concurrent BV status, suggesting there may be a synergistic effect of M. genitalium and BV on fecundability. This work was supported by a National Institutes of Health grant (NICHD R01 HD087346-RSM). R.S.M. received additional support for mentoring (NICHD K24 HD88229). E.M.L. was supported by pre- and post-doctoral fellowships (NIAID T32 AI07140, NICHD F32 HD100202). Data collection and management were completed using REDCap electronic data capture tools hosted at the University of Washington's Institute of Translational Health Science supported by grants from NCATS/NIH (UL1 TR002319). The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. R.S.M. receives research funding, paid to the University of Washington, from Hologic Corporation and consulting fees from Lupin Pharmaceuticals. L.E.M. receives research funding and material for research studies, paid to the University of Washington, from Hologic Corporation and Nabriva Therapeutics, travel support from Hologic, and consulting fees from Health Advances. E.M.L.'s contributions to this study primarily occurred while affiliated with the University of Washington; at the time of submission, E.M.L. was an employee of and holds stock or stock grants for AbbVie, Inc. The other authors have no conflicts of interest. N/A.
Identifiants
pubmed: 37634090
pii: 7252363
doi: 10.1093/humrep/dead172
pmc: PMC10546078
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
2020-2027Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR002319
Pays : United States
Organisme : NICHD NIH HHS
ID : F32 HD100202
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007140
Pays : United States
Organisme : NICHD NIH HHS
ID : K24 HD088229
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD087346
Pays : United States
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Lancet. 2002 Jul 13;360(9327):151-9
pubmed: 12126838
Hum Reprod. 2021 Apr 20;36(5):1279-1287
pubmed: 33594429
Infect Immun. 2021 Apr 16;89(5):
pubmed: 33558324
Sex Transm Dis. 2013 Feb;40(2):117-22
pubmed: 23324974
Clin Microbiol Rev. 2011 Jul;24(3):498-514
pubmed: 21734246
J Clin Microbiol. 1991 Feb;29(2):297-301
pubmed: 1706728
Am J Epidemiol. 1989 May;129(5):1072-8
pubmed: 2705427
Sex Transm Dis. 2021 Nov 1;48(11):e160-e162
pubmed: 33560093
J Eur Acad Dermatol Venereol. 2022 May;36(5):641-650
pubmed: 35182080
Am J Epidemiol. 2017 Jul 15;186(2):194-201
pubmed: 28472225
J Reprod Fertil. 1985 Jan;73(1):237-40
pubmed: 3881583
AIDS. 2020 Oct 1;34(12):1725-1733
pubmed: 32701583
Int J STD AIDS. 2019 Sep;30(10):938-950
pubmed: 31280688
Clin Infect Dis. 2015 Aug 1;61(3):418-26
pubmed: 25900174
Hum Reprod. 2003 Oct;18(10):2103-9
pubmed: 14507829
Am J Obstet Gynecol. 2021 Aug;225(2):157.e1-157.e9
pubmed: 33716075
Fertil Steril. 2008 Sep;90(3):513-20
pubmed: 17548070
BMC Womens Health. 2020 Mar 26;20(1):62
pubmed: 32216785
Sex Transm Infect. 2001 Dec;77(6):402-8
pubmed: 11714935
J Infect Dis. 2016 Jun 15;213(12):1932-7
pubmed: 26908758
Am J Reprod Immunol. 2018 Dec;80(6):e13065
pubmed: 30375712
Sex Transm Dis. 2022 Feb 1;49(2):139-144
pubmed: 34321450
JAMA. 2021 Sep 14;326(10):949-956
pubmed: 34519796
Am J Reprod Immunol. 2014 Jun;71(6):555-63
pubmed: 24832618
Hum Reprod. 2007 Apr;22(4):968-79
pubmed: 17158214
Fertil Steril. 2015 Nov;104(5):1104-10
pubmed: 26364838
Clin Infect Dis. 2021 Apr 8;72(7):1181-1189
pubmed: 32052831
Hum Reprod. 2001 Sep;16(9):1866-74
pubmed: 11527890
Reproduction. 2012 Dec;144(6):661-8
pubmed: 23028125
Nat Rev Immunol. 2017 Aug;17(8):469-482
pubmed: 28627518
Sex Transm Dis. 2007 Nov;34(11):864-9
pubmed: 17621244
MMWR Recomm Rep. 2021 Jul 23;70(4):1-187
pubmed: 34292926
Paediatr Perinat Epidemiol. 2013 Sep;27(5):491-502
pubmed: 23930785
J Infect Dis. 2016 Jun 1;213(11):1828-35
pubmed: 26783349
Womens Health (Lond). 2021 Jan-Dec;17:17455065211009181
pubmed: 33866885
J Sex Marital Ther. 2015;41(6):610-25
pubmed: 25211377
J Infect Dis. 2013 Jun 15;207(12):1857-68
pubmed: 23493725
Sex Transm Infect. 2016 Sep;92(6):441-6
pubmed: 26825087
BMJ. 2020 Nov 11;371:m3966
pubmed: 33177047
Clin Infect Dis. 2018 Jun 18;67(1):73-79
pubmed: 29342269
Sex Transm Infect. 2005 Dec;81(6):463-6
pubmed: 16326847
Sex Transm Infect. 2008 Oct;84(5):338-42
pubmed: 18445635
BMJ Open. 2020 Feb 25;10(2):e035186
pubmed: 32102825
Stat Med. 1994 Mar 15-Apr 15;13(5-7):671-81
pubmed: 8023042